H. Autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

D. Sur, Eau disponible pour l'utilisation, 2017.

N. Mallouk, C. Labruyère, and J. L. Reny, Prevalence of poor biological response to clopidogrel, Thromb Haemost, vol.107, issue.3, pp.494-506, 2012.

J. S. Hulot, A. Burat, and E. Villard, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, vol.108, issue.7, pp.2244-2247, 2006.

A. Bura, C. Bachelot-loza, F. D. Ali, M. Aiach, and P. Gaussem, Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects, Journal of Thrombosis and Haemostasis, vol.4, issue.9, pp.2096-2097, 2006.

, Thromb Haemost, vol.4, issue.4, pp.2096-2103, 2006.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

S. Matetzky, B. Shenkman, and V. Guetta, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, ACC Current Journal Review, vol.13, issue.9, p.9, 2004.

S. Cho, S. W. Lau, V. Tandon, K. Kumi, E. Pfuma et al., Geriatric Drug Evaluation, Archives of Internal Medicine, vol.171, issue.10, 2011.

K. R. Machlus and J. E. Italiano, The incredible journey: From megakaryocyte development to platelet formation, Journal of Cell Biology, vol.201, issue.6, pp.785-796, 2013.

M. R. Boisseau, 05 Hémostase : endothélium, Willebrand et hémophilie, Hématologie, vol.26, issue.S4, pp.48-54, 2020.

K. A. Jacobson, F. Deflorian, S. Mishra, and S. Costanzi, Pharmacochemistry of the platelet purinergic receptors, Purinergic Signalling, vol.7, issue.3, pp.305-324, 2011.

M. Cattaneo, P2Y12receptors: structure and function, Journal of Thrombosis and Haemostasis, vol.13, pp.S10-S16, 2015.

C. Gachet, Les mécanismes moléculaires de l?activation plaquettaire, Bulletin de l'Académie Nationale de Médecine, vol.197, issue.2, pp.361-373, 2013.

D. Vidal, Céline Masson, Michel Gad Wolkowicz (éd.), La force du nom. Leur nom, ils l'ont changé, Archives de sciences sociales des religions, issue.156, p.219, 2011.

. Caprie-steering-committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), The Lancet, vol.348, issue.9038, pp.1329-1339, 1996.

S. R. Mehta and S. Yusuf, The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, European Heart Journal, vol.21, issue.24, pp.2033-2041, 2000.

M. S. Sabatine, C. P. Cannon, and C. M. Gibson, Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction With ST-Segment Elevation, ACC Current Journal Review, vol.14, issue.6, p.1, 2005.

, Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.360, issue.20, pp.2066-2078, 2009.

Z. M. Chen, L. X. Jiang, and Y. P. Chen, Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial, The Lancet, vol.366, issue.9497, pp.1607-1621, 2005.

M. De, . Sanofi-aventis, and . Plavix®, , 2016.

D. Sur, http://ljournal.ru/wp-content/uploads/2017/03/a-2017-023.pdf, 2017.

S. Yusuf, F. Zhao, and M. Sr, Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation, New England Journal of Medicine, vol.345, issue.7, pp.494-502, 2001.

U. Klinkhardt, C. M. Kirchmaier, D. Westrup, J. Graff, R. Mahnel et al., Ex vivo?in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A, Clinical Pharmacology & Therapeutics, vol.67, issue.3, pp.305-313, 2000.

J. Szymezak and P. Gaussem, Inhibiteurs de la pompe à protons et clopidogrel (Plavix®) : une liaison dangereuse ?, La Revue de Médecine Interne, vol.34, issue.2, pp.99-104, 2013.

C. S. Kwok and Y. K. Loke, Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel, Drug Safety, vol.35, issue.2, pp.127-139, 2012.

P. I. Hsu, K. H. Lai, and C. P. Liu, Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis, Gastroenterology, vol.140, issue.3, pp.791-798.e2, 2011.

Y. Takeuchi, C. Ohishi, K. Arai, and M. Imawari, The Natural Course of Ulcerative Proctitis in Japan: Disease Extension and Related Factors, Gastroenterology, vol.140, issue.5, pp.S-791, 2011.

D. L. Bhatt, B. L. Cryer, and C. F. Contant, Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med, vol.363, issue.20, pp.1909-1926, 2010.

J. Pang, Q. Wu, Z. Zhang, T. Zheng, Q. Xiang et al., Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention, IJC Heart & Vasculature, vol.23, p.100317, 2019.

H. Shuo and J. Yuanzhe, GW24-e2973 Safety of clopidogrel and proton pump inhibitors in patients undergoing percutaneous coronary intervention; A meta-analysis, Heart, vol.99, issue.Suppl 3, pp.A246.1-A246, 2013.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

J. M. Siller-matula, I. Lang, G. I. Christ, and B. Jilma, Calcium channel blockers reduce the antiplatelet effect of clopidogrel, BMC Pharmacology, vol.8, issue.S1, p.47, 2008.

S. Aggarwal, R. S. Loomba, and R. R. Arora, Effects of Concurrent Calcium Channel Blocker on Antiplatelet Efficacy of Clopidogrel Therapy, American Journal of Therapeutics, vol.23, issue.1, pp.e29-e36, 2016.

S. Aggarwal, R. S. Loomba, and R. R. Arora, Effects of Concurrent Calcium Channel Blocker on Antiplatelet Efficacy of Clopidogrel Therapy, American Journal of Therapeutics, vol.23, issue.1, pp.e29-e36, 2016.

A. Van-hecken, M. Depré, and K. Wynants, Effect of clopidogrel on naproxeninduced gastrointestinal blood loss in healthy volunteers, Drug Metabol Drug Interact, vol.14, issue.3, pp.193-205, 1998.

K. H. Tay, D. A. Lane, and G. Y. Lip, Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?, Thrombosis and Haemostasis, vol.100, issue.12, pp.955-957, 2008.

K. A. Fox, K. F. Carruthers, D. R. Dunbar, C. Graham, J. R. Manning et al., Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study), European Heart Journal, vol.31, issue.22, pp.2755-2764, 2010.

D. Attias, B. Besse, and N. Lellouche, Cardiologie Vasculaire. Edition, 2010.

H. Autorité-de-santé, Avis de la commission de la transparence du 20 janvier, 2016.

D. Sur,

H. Autorité-de-santé,

, Le programme principal disponible en ligne, PrimaryCare, vol.11, issue.12, pp.211-211, 2011.

H. Autorité-de-santé, Bon usage des agents antiplaquettaires. Juin 2012, Journal Européen des Urgences et de Réanimation, vol.24, issue.3, pp.180-186, 2012.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Kardiologia Polska, vol.37, pp.1359-1469, 2016.

J. Rodés-cabau, H. L. Dauerman, M. G. Cohen, R. Mehran, E. M. Small et al., Antithrombotic Treatment in Transcatheter Aortic Valve Implantation, Journal of the American College of Cardiology, vol.62, issue.25, pp.2349-2359, 2013.

A. Godier, P. Fontana, S. Motte, A. Steib, F. Bonhomme et al., Gestion des agents antiplaquettaires pour une procédure invasive programmée. Propositions du Groupe d?intérêt en hémostase périopératoire (GIHP) et du Groupe français d?études sur l?hémostase et la thrombose (GFHT) en collaboration avec la Société française d?anesthésie-réanimation (SFAR), Anesthésie & Réanimation, vol.4, issue.6, pp.548-562, 2018.

, Anesth Reanim, vol.40, issue.6, pp.548-562, 2012.

J. Peters, Voir le littéraire : la visualisation de données et le Projet des Registres de la Comédie-Française, Données, recettes & répertoire: La scène en ligne (1680-1793), 2020.

A. Alquahtani and G. Moe, Développements macro-économiques au Portugal, Cardiologie Conférences Scientifiques, vol.XIII, 2008.

P. Harrison, Measuring platelet function?, Hematol J, vol.5, issue.3, pp.164-173, 2004.

A. Pacull, Biologie des anomalies de l'hémostase : Tome III test photométrique d'agrégation plaquettaire. Haute Autorité de Santé, Rapport d'évaluation technologique, 2011.

, Standardization of Platelet Function Testing by Aggregometry Through New CLSI Guideline, Laboratory Medicine, vol.40, issue.5, pp.269-270, 2009.

K. Koltai, G. Kesmarky, G. Feher, A. Tibold, and K. Toth, Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications, International Journal of Molecular Sciences, vol.18, issue.8, p.1803, 2017.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, D. Caterina et al.,

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

E. Oikonomou, N. Papageorgiou, and S. Papaioannou, Genetic testing and antiplatelet treatment : still way to go ?, International Journal of Cardiology, vol.187, pp.63-65, 2015.

S. Ross, S. Nejat, and G. Paré, Use of genetic data to guide therapy in arterial disease, Journal of Thrombosis and Haemostasis, vol.13, pp.S281-S289, 2015.

, J Thromb Haemost, vol.13, issue.1, pp.281-289, 2015.

R. Marcucci, A. M. Gori, R. Paniccia, B. Giusti, S. Valente et al., Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay, Circulation, vol.119, issue.2, pp.237-242, 2009.

M. J. Price, S. Endemann, and R. R. Gollapudi, Prognostic significance of postclopidogrel platelet reactivity assessed by a pointof-care assay on thrombotic events after drug-eluting stent implantation, Eur Heart J, vol.29, pp.992-1000, 2008.

H. Ge, Y. Zhou, and X. Liu, Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty, Angiology, vol.63, issue.1, pp.62-68, 2012.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

N. L. Hurst, V. B. Nooney, B. Raman, Y. Y. Chirkov, R. De-caterina et al., Clopidogrel ?resistance?: Pre- vs post-receptor determinants, Vascular Pharmacology, vol.59, issue.5-6, pp.152-161, 2013.

Z. Motovska, P. Widimsky, and R. Petr, Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking 'paradox, J Cardiovasc Pharmacol, vol.53, issue.5, pp.368-72, 2009.

H. Maruyama, T. Fukuoka, and I. Deguchi, Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients, Intern Med, vol.53, pp.2575-2579, 2014.

F. Zaccardi, D. Pitocco, P. Willeit, and J. A. Laukkanen, Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials, Atherosclerosis, vol.240, issue.2, pp.439-445, 2015.

P. Fontana and J. L. Reny, Clopidogrel en pratique : indications, résistance et tests biologiques chez les patients avec affections vasculaires, Rev Med Suisse, 2008.

S. Jun-feng, X. , H. Cheng-yan, and L. , Risk factors for clopidogrel resistance in patient with ischemic cerebral infarction and the correlation with ABCB1 rs1045642 polymophism. Experimental and therapeutic medicine, vol.9, pp.267-271, 2015.

F. Uzun, I. Biyik, and I. A. Akturk, Antiplatelet resistance and the role of associated variables in stable patients treated with stenting, Postep Kardiol Inter, 2015.

S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart et al., Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction, Circulation, vol.109, issue.25, pp.3171-3175, 2004.

A. Fiolaki, A. H. Katsanos, and A. P. Kyritsis, High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis, J Neurol Sci, vol.376, pp.112-116, 2017.

G. Siasos, E. Oikonomou, and M. Vavuranakis, Platelet Activation, and Cardiovascular Outcome in Patients after .Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance, Cardiology, vol.137, issue.2, pp.104-113, 2017.

C. Gallego-fabrega, C. Carrera, and J. L. Reny, TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke, Stroke, vol.47, issue.5, pp.1180-1186, 2016.

J. L. Reny, P. Berdagué, A. Poncet, I. Barazer, S. Nolli et al., Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients, Circulation, vol.125, issue.25, pp.3201-3210, 2012.

J. Song and Y. S. Shin, Antiplatelet drug resistance did not increase the thromboembolic events after stent-assisted coiling of unruptured intracranial aneurysm: a single center experience of 99 cases, Neurological Sciences, vol.38, issue.5, pp.879-885, 2017.

D. Legrand, E. Barbato, P. Chenu, J. Magne, M. Vrolix et al., The STIB score: a simple clinical test to predict clopidogrel resistance, Acta Cardiologica, vol.70, issue.5, pp.516-521, 2015.

V. Legrand, T. Cuisset, P. Chenu, M. Vrolix, C. Martinez et al., Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial, EuroIntervention, vol.10, issue.2, pp.204-211, 2014.

A. Corsonello, C. Pedone, and R. Incalzi, Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions, Current Medicinal Chemistry, vol.17, issue.6, pp.571-584, 2010.

M. W. Bowie and P. W. Slattum, Pharmacodynamics in Older Adults: A Review, The American Journal of Geriatric Pharmacotherapy, vol.5, issue.3, pp.263-303, 2007.

J. H. Gurwitz, T. S. Field, and L. R. Harrold, Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting, JAMA, vol.289, issue.9, p.1107, 2003.

C. Palleria, D. Paolo, A. Giofrè, and C. , Pharmacokinetic drug-drug interaction and their implication in clinical management, J Res Med Sci, vol.18, issue.7, pp.601-611, 2013.

T. Juárez-cedillo, C. Martinez-hernández, A. Hernández-constantino, J. C. Garcia-cruz, A. M. Avalos-mejia et al., Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly, Basic & Clinical Pharmacology & Toxicology, vol.118, issue.4, pp.298-305, 2015.

T. Juárez-cedillo, C. Martinez-hernández, A. Hernández-constantino, J. C. Garcia-cruz, A. M. Avalos-mejia et al., Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly, Basic & Clinical Pharmacology & Toxicology, vol.118, issue.4, pp.298-305, 2015.

L. Pasina, C. D. Djade, A. Nobili, M. Tettamanti, C. Franchi et al., Drug-drug interactions in a cohort of hospitalized elderly patients, Pharmacoepidemiology and Drug Safety, vol.22, issue.10, pp.n/a-n/a, 2013.

L. Mallet, A. Spinewine, and A. Huang, The challenge of managing drug interactions in elderly people, The Lancet, vol.370, issue.9582, pp.185-191, 2007.

E. R. Hajjar, A. C. Cafiero, and J. T. Hanlon, Polypharmacy in elderly patients, The American Journal of Geriatric Pharmacotherapy, vol.5, issue.4, pp.345-351, 2007.

C. Franchi, M. Tettamanti, L. Pasina, C. D. Djignefa, I. Fortino et al., Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM?Elderly Project 2000?2010, European Journal of Clinical Pharmacology, vol.70, issue.4, pp.437-443, 2014.

S. H. Tella and J. C. Gallagher, Biological agents in management of osteoporosis, European Journal of Clinical Pharmacology, vol.70, issue.11, pp.1291-1301, 2014.

A. Cherubini, A. Corsonello, and F. Lattanzio, Polypharmacy in Nursing Home Residents: What Is the Way Forward?, Journal of the American Medical Directors Association, vol.17, issue.1, pp.4-6, 2016.

N. Jokanovic, E. C. Tan, M. J. Dooley, C. M. Kirkpatrick, and J. S. Bell, Prevalence and Factors Associated With Polypharmacy in Long-Term Care Facilities: A Systematic Review, Journal of the American Medical Directors Association, vol.16, issue.6, pp.535.e1-535.e12, 2015.

J. Tjia, M. R. Rothman, D. K. Kiely, M. L. Shaffer, H. M. Holmes et al., Daily Medication Use in Nursing Home Residents with Advanced Dementia, Journal of the American Geriatrics Society, vol.58, issue.5, pp.880-888, 2010.

A. Cherubini, A. Corsonello, and F. Lattanzio, Underprescription of Beneficial Medicines in Older People, Drugs & Aging, vol.29, issue.6, pp.463-475, 2012.

A. Corsonello, C. Pedone, F. Lattanzio, M. Lucchetti, S. Garasto et al., Potentially Inappropriate Medications and Functional Decline in Elderly Hospitalized Patients, Journal of the American Geriatrics Society, vol.57, issue.6, pp.1007-1014, 2009.

N. Shehab, M. C. Lovegrove, A. I. Geller, K. O. Rose, N. J. Weidle et al., US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014, JAMA, vol.316, issue.20, p.2115, 2016.

S. Legrains, H. Autorité-de, and . Santé, Consommation médicamenteuse chez le sujet âgé : consommation, prescription, iatrogénie et observance, 2005.

F. Lancon and J. Viguier, Enquête sur la mammographie dans le programme de dépistage organisé du cancer du sein (DOCS), Revue d'Épidémiologie et de Santé Publique, vol.61, p.S278, 2013.

. __16_44_51_580 and . Pdf, Consulté le 23 Février, 2019.

J. Emeriau, A. Fourrier, J. Dartigues, B. Begaud, D. Pellerin et al.,

S. Pariel-madjlessi, Les troubles du comportement chez les personnes âgées, L'infirmier et les soins aux personnes âgées, vol.182, pp.175-182, 2005.

J. Doucet, A. Jego, D. Noel, C. E. Geffroy, C. Capet et al., Preventable and Non-Preventable Risk Factors for Adverse Drug Events Related to Hospital Admissions in the Elderly, Clinical Drug Investigation, vol.22, issue.6, pp.385-392, 2002.

J. H. Gurwitz, T. S. Field, and L. R. Harrold, Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting, JAMA, vol.289, issue.9, p.1107, 2003.

M. Laroche, F. Bouthier, L. Merle, and J. L. Charmes, Médicaments potentiellement inappropriés aux personnes âgées : intérêt d?une liste adaptée à la pratique médicale française, La Revue de Médecine Interne, vol.30, issue.7, pp.592-601, 2009.

P. J. Barry, P. Gallagher, C. Ryan, and D. O'mahony, START (screening tool to alert doctors to the right treatment) an evidence-based screening tool to detect prescribing omissions in elderly patients, Age and Ageing, vol.36, issue.6, pp.632-638, 2007.

P. Gallagher and D. O'mahony, STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria, Age and Ageing, vol.37, issue.6, pp.673-679, 2008.

R. M. Wright, R. Sloane, C. F. Pieper, C. Ruby-scelsi, J. Twersky et al., Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: Results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study, The American Journal of Geriatric Pharmacotherapy, vol.7, issue.5, pp.271-280, 2009.

, JGA News, Digestion, vol.80, issue.4, pp.271-271, 2009.

R. Tamblyn, R. Laprise, and J. A. Hanley, Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons, JAMA, vol.285, issue.4, p.421, 2001.

C. Motte, Optimisation diagnostique et thérapeutique chez la personne âgée : application de l'outil PMSA (prescription médicamenteuse chez la personne âgée)

M. Andro, S. Estivin, and A. Gentric, Prescriptions médicamenteuses en gériatrie : overuse (sur-utilisation), misuse (mauvaise utilisation), underuse (sous-utilisation). Analyse qualitative à partir des ordonnances de 200 patients entrant dans un service de court séjour gériatrique, La Revue de Médecine Interne, vol.33, issue.3, pp.122-127, 2012.

N. Faculté-de-médecine-de, Notice d'utilisation du fabricant, vol.107, 2016.

, Prise de position sur le dossier du patient en ligne, PrimaryCare, vol.9, issue.16, pp.298-299, 2009.

L. Lin, H. Wang, Y. F. Chen, W. Lin, C. Wang et al., High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention, Coronary Artery Disease, vol.26, issue.5, pp.386-395, 2015.

H. Choi, J. Ryu, H. Seo, M. Kang, and E. Kim, Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?, International Journal of Clinical Pharmacy, vol.37, issue.5, pp.758-761, 2015.

L. Wallentin, R. C. Becker, and A. Budaj, Ticagrelor versus Clopidogrel in patients with acute coronary syndromes, N Engl J Med, vol.361, pp.1045-57, 2009.

D. Wang, X. H. Yang, J. D. Zhang, R. B. Li, M. Jia et al., Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis, BMC Cardiovascular Disorders, vol.18, issue.1, p.217, 2018.

W. R. Hiatt, F. G. Fowkes, G. Heizer, J. S. Berger, I. Baumgartner et al., Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease, New England Journal of Medicine, vol.376, issue.1, pp.32-40, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02048713

E. M. Warlo, H. Arnesen, and I. Seljeflot, A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease, Thrombosis Journal, vol.17, issue.1, p.11, 2019.

A. E. Rodriguez, A. M. Rodriguez-granillo, S. D. Ascarrunz, F. Peralta--bazan, and M. Y. Cho, Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis, Current Pharmaceutical Design, vol.24, issue.4, pp.465-477, 2018.

, Quellenregister, Schuldrecht des Bürgerlichen Gesetzbuches, vol.24, pp.465-477, 1931.

J. Silvain, G. Cayla, J. S. Hulot, J. Finzi, M. Kerneis et al., High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study, European Heart Journal, vol.33, issue.10, pp.1241-1249, 2011.